The effect of the family history of diabetes on glucose metabolism of the patients recieving atypical antipsychotics; [Atipik antipsikotik kullanan hastalarda ailede diyabet öykü sü olmasinin glukoz metabolizmasi üzerine olan etkisi]
No Thumbnail Available
Date
2007
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Objective: Diabetes is observed 2-3 times more frequently in schizophrenic patients with comparison to the general population. Recently, many publications have reported diabetes related to atypical antipsychotics. Risk factors such as age, ethnicity, overweight, duration of obesity, physical activity, and family history of diabetes seem to help development of diabetes. This study aims to investigate how the glucose metabolism is affected from familial history of diabetes which is a risk factor for the disease. Method: Seventy patients who have a diagnosis of schizophrenia or other psychotic disorders and are treated with atypical antipsychotics for at least one year were recruited for the study. The patients were divided into two groups defined as those with or without a family history of diabetes. In order to evaluate the glucose metabolism fasting blood glucose, oral glucose tolerance, blood insuline, c-peptide, hemoglobine A1c, leptin and ghrelin levels were measured. Results: The results of the comparison of fasting blood glucose, oral glucose tolerance, blood insuline, c-peptide, hemoglobine A1c, leptin and ghrelin levels between two patient groups with and without family history of diabetesonly ghrelin levels were found to be statistically higher in the group of patients with a history of diabetes in their family; no other parameters have statistically significant differencesbetween two groups. Conclusion: Having a family history of diabetes may increase the probabality of disturbance in glucose metabolism of the patients receiving atypical antipsychotics. It would be reasonable to evaluate the risk factors prior to the treatment and routinely review the parameters required to evaluate the metabolic side effects in clinical follow-ups.
Description
Keywords
amisulpride , atypical antipsychotic agent , C peptide , clozapine , ghrelin , hemoglobin A1c , insulin , leptin , olanzapine , quetiapine , risperidone , age , article , diabetes mellitus , ethnicity , family history , glucose blood level , glucose metabolism , human , insulin blood level , major clinical study , obesity , oral glucose tolerance test , risk factor , schizophrenia , statistical analysis